Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 31, 2026 16:57 ET | Source: 20/20 Biolabs Inc.

20/20 BioLabs Reports Full Year 2025 Financial Results and Recent Operational Progress

20/20 BioLabs Reports Full Year 2025 Financial Results and Recent Operational Progress
March 31, 2026 15:36 ET | Source: Pomerantz LLP

Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc. and Certain Officers – INO

NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ: INO) and...
March 31, 2026 12:41 ET | Source: SOCIETE GENERALE SFH

Societe Generale SFH: Availability of the Annual Financial Report for 2025

SOCIETE GENERALE SFH: AVAILABILITY OF THE ANNUAL FINANCIAL REPORT FOR 2025 Regulated Information Paris, 31 March 2026 Societe Generale SFH (“Société de Financement de l’Habitat”, Home Loans SFH)...
March 31, 2026 12:20 ET | Source: SOCIETE GENERALE SCF

Societe Generale SCF: Availability of the Annual Financial Report for 2025

SOCIETE GENERALE SCF: AVAILABILITY OF THE ANNUAL FINANCIAL REPORT FOR 2025 Regulated Information Paris, 31 March 2026 Societe Generale SCF (“Société de Crédit Foncier”, Public Sector Loans) hereby...
March 31, 2026 09:45 ET | Source: Trethera Corporation

Trethera Announces Massachusetts General Hospital Clinical Trial Collaboration to Evaluate TRE-515 in ALS Patients

MGH collaboration to evaluate TRE-515 in ALS patients, advancing development of a first-in-class therapy targeting inflammation and nucleotide metabolism.
March 31, 2026 09:15 ET | Source: MAIA Biotechnology, Inc.

MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer

Potential breakthrough therapeutic targets $50B+ global immunotherapy market1 CHICAGO, March 31, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a...
March 31, 2026 08:35 ET | Source: Research and Markets

Japan's Cell and Gene Therapy Market Set to Grow Tenfold by 2035, Reaching USD 5.15 Billion: Pre-commercial Scale Manufacturing Leads Market Expansion

Dublin, March 31, 2026 (GLOBE NEWSWIRE) -- The "Japan Cell and Gene Therapy Manufacturing Market: Industry Trends and Future Forecast, Till 2035 - Distribution by Type of Therapy, Type of Scale,...
March 31, 2026 08:00 ET | Source: YD Bio Limited

YD Bio and EG BioMed Jointly Launch Nationwide Telehealth Platform to Accelerate Commercialization of Cancer Detection and Decentralized Clinical Services Across the United States

Taipei, Taiwan, March 31, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and...
March 31, 2026 08:00 ET | Source: Imunon, Inc.

IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study

IMNN-001 is the first frontline immunotherapy to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with advanced ovarian cancer Final Phase 2...
March 31, 2026 08:00 ET | Source: Allarity Therapeutics, Inc.

Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress

Strengthened financial position through disciplined cost management, with a year-end 2025 cash position of $14.7 million and runway into mid-2028Received FDA Fast Track designation for...